Pt. 3 - Live at AMCP Annual 2024: Ben Urick gives overview of GLP-1 data as it relates to weight ...

Four of the Prime studies presented at AMCP relate to glucagon-like peptide-1 agonist - or GLP-1 - drugs. Earlier analysis of real-world data showed low adherence and increased cost of care for individuals in the first year of GLP-1 therapy. Prime has been a leader in GLP-1 insights, and three studies at AMCP take a fresh look at the GLP-1 data as it relates to weight loss. We have Ben Urick, Health Outcomes Reseach Senior Principal from Prime, here to walk us through the research.